Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Bewersdorf JP, Stahl M, Zeidan AM.

Expert Rev Anticancer Ther. 2019 Mar 19:1-12. doi: 10.1080/14737140.2019.1589374. [Epub ahead of print]

PMID:
30887841
2.

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):211-219. doi: 10.6004/jnccn.2018.7095.

3.

Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?

Vandsemb EN, Kim TK, Zeidan AM.

Cancer. 2019 Mar 12. doi: 10.1002/cncr.32042. [Epub ahead of print] No abstract available.

PMID:
30861094
4.

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

Bewersdorf JP, Shallis R, Stahl M, Zeidan AM.

Ther Adv Hematol. 2019 Jan 11;10:2040620718816698. doi: 10.1177/2040620718816698. eCollection 2019. Review.

5.

Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?

Bewersdorf JP, Stahl M, Zeidan AM.

Leuk Lymphoma. 2019 Jan 17:1-16. doi: 10.1080/10428194.2018.1546854. [Epub ahead of print]

PMID:
30652518
6.

Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.

Zeidan AM, Klink AJ, McGuire M, Feinberg B.

Leuk Lymphoma. 2019 Jan 14:1-6. doi: 10.1080/10428194.2018.1551538. [Epub ahead of print]

PMID:
30636526
7.

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

Liu Y, Bewersdorf JP, Stahl M, Zeidan AM.

Blood Rev. 2019 Mar;34:67-83. doi: 10.1016/j.blre.2018.12.001. Epub 2018 Dec 5. Review.

PMID:
30553527
8.

Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.

Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH.

Ann Hematol. 2019 Feb;98(2):339-350. doi: 10.1007/s00277-018-3539-7. Epub 2018 Nov 9.

PMID:
30413901
9.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

Blood Adv. 2018 Oct 23;2(20):2681-2690. doi: 10.1182/bloodadvances.2018021436.

10.

Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.

Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X.

Blood Rev. 2019 Mar;34:1-15. doi: 10.1016/j.blre.2018.09.001. Epub 2018 Sep 21. Review.

PMID:
30314642
11.

Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.

Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ.

Cancer. 2018 Nov 1;124(21):4211-4220. doi: 10.1002/cncr.31688. Epub 2018 Sep 14.

PMID:
30216436
12.

Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice.

Shallis RM, Xu ML, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM.

Ann Hematol. 2018 Dec;97(12):2333-2343. doi: 10.1007/s00277-018-3474-7. Epub 2018 Aug 14.

PMID:
30109425
13.

Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.

Shallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM.

Ann Hematol. 2018 Nov;97(11):2245-2248. doi: 10.1007/s00277-018-3459-6. Epub 2018 Aug 7. Review. No abstract available.

PMID:
30088044
14.

Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts.

Shallis RM, Ahmad R, Zeidan AM.

Eur J Haematol. 2018 Dec;101(6):711-720. doi: 10.1111/ejh.13153. Epub 2018 Oct 10. Review.

PMID:
30055055
15.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

16.

Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.

Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S.

Ann Hematol. 2019 Jan;98(1):237-240. doi: 10.1007/s00277-018-3427-1. Epub 2018 Jul 19. No abstract available.

PMID:
30027436
17.

Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.

Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM.

Expert Rev Hematol. 2018 Sep;11(9):715-726. doi: 10.1080/17474086.2018.1503049. Epub 2018 Aug 22. Review.

PMID:
30024293
18.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.

Leuk Lymphoma. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893. Epub 2018 Jul 2. No abstract available.

PMID:
29963936
19.

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD.

Blood Cancer J. 2018 Jun 11;8(6):55. doi: 10.1038/s41408-018-0081-8. No abstract available.

20.

The genetic and molecular pathogenesis of myelodysplastic syndromes.

Shallis RM, Ahmad R, Zeidan AM.

Eur J Haematol. 2018 Sep;101(3):260-271. doi: 10.1111/ejh.13092. Epub 2018 Jul 12. Review.

PMID:
29742289
21.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD.

Clin Cancer Res. 2018 Aug 1;24(15):3519-3527. doi: 10.1158/1078-0432.CCR-17-3763. Epub 2018 May 1.

PMID:
29716921
22.

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

Uy N, Nadeau M, Stahl M, Zeidan AM.

J Blood Med. 2018 Apr 13;9:67-74. doi: 10.2147/JBM.S136575. eCollection 2018. Review.

23.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.

24.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219. [Epub ahead of print] No abstract available.

PMID:
29667455
25.

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9.

PMID:
29649620
26.

The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.

Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM.

Am J Hematol. 2018 Jul;93(7):943-952. doi: 10.1002/ajh.25103. Epub 2018 Apr 28. Review.

PMID:
29635754
27.

To chelate or not to chelate in MDS: That is the question!

Zeidan AM, Griffiths EA.

Blood Rev. 2018 Sep;32(5):368-377. doi: 10.1016/j.blre.2018.03.002. Epub 2018 Mar 8. Review.

PMID:
29602612
28.

Improved JAK Inhibition in Myelofibrosis-The Long Road Ahead.

Stahl M, Zeidan AM.

JAMA Oncol. 2018 May 1;4(5):659-660. doi: 10.1001/jamaoncol.2017.5802. No abstract available.

PMID:
29522105
29.
30.

Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?

Shallis RM, Zeidan AM.

Leuk Lymphoma. 2018 Sep;59(9):2015-2017. doi: 10.1080/10428194.2018.1430797. Epub 2018 Feb 7. No abstract available.

PMID:
29411698
31.

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ.

Blood. 2018 Feb 15;131(7):818-821. doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19. No abstract available.

32.

Risk stratification in therapy-related myelodysplastic syndromes.

Zeidan AM.

Oncotarget. 2017 Sep 24;8(46):80103-80104. doi: 10.18632/oncotarget.21178. eCollection 2017 Oct 6. No abstract available.

33.

Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?

Zeidan AM.

Leuk Lymphoma. 2018 May;59(5):1030-1032. doi: 10.1080/10428194.2017.1382700. Epub 2017 Sep 27. No abstract available.

PMID:
28952833
34.

Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.

Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ.

PLoS One. 2017 Sep 13;12(9):e0184747. doi: 10.1371/journal.pone.0184747. eCollection 2017.

35.

Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.

Zeidan AM, Pullarkat VA, Komrokji RS.

Crit Rev Oncol Hematol. 2017 Sep;117:57-66. doi: 10.1016/j.critrevonc.2017.07.002. Epub 2017 Jul 12. Review.

PMID:
28807236
36.

US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box.

Zeidan AM, Gore SD, Davidoff AJ.

J Clin Oncol. 2017 Oct 1;35(28):3264. doi: 10.1200/JCO.2017.74.3104. Epub 2017 Aug 8. No abstract available.

PMID:
28787256
37.

Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.

Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X.

J Clin Oncol. 2017 Oct 20;35(30):3417-3424. doi: 10.1200/JCO.2017.72.7149. Epub 2017 Aug 7.

38.

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD.

Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31. Review.

39.

Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.

Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczesny S, Konig H.

Int J Mol Sci. 2017 Jul 31;18(8). pii: E1660. doi: 10.3390/ijms18081660. Review.

40.

The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies.

Li AW, Yin ES, Stahl M, Kim TK, Panse G, Zeidan AM, Leventhal JS.

Blood Rev. 2017 Nov;31(6):370-388. doi: 10.1016/j.blre.2017.07.003. Epub 2017 Jul 14. Review.

PMID:
28732587
41.

Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Stahl M, Lu BY, Kim TK, Zeidan AM.

Target Oncol. 2017 Aug;12(4):413-447. doi: 10.1007/s11523-017-0503-8. Review.

PMID:
28664386
42.

Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.

Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF.

Cancer. 2017 Oct 1;123(19):3763-3771. doi: 10.1002/cncr.30818. Epub 2017 Jun 22.

43.

Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ.

Cancer. 2017 Oct 1;123(19):3754-3762. doi: 10.1002/cncr.30814. Epub 2017 Jun 16.

44.

Management of myelofibrosis: JAK inhibition and beyond.

Stahl M, Zeidan AM.

Expert Rev Hematol. 2017 May;10(5):459-477. doi: 10.1080/17474086.2017.1317590. Epub 2017 Apr 26. Review.

PMID:
28395559
45.

Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.

Stahl M, Zeidan AM.

Expert Rev Hematol. 2017 Apr;10(4):345-364. doi: 10.1080/17474086.2017.1297704. Epub 2017 Mar 9. Review.

PMID:
28277851
46.

Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.

Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J.

Ann Hematol. 2017 Jun;96(6):1037-1039. doi: 10.1007/s00277-017-2954-5. Epub 2017 Feb 20. No abstract available.

PMID:
28220192
47.

Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.

Stahl M, Zeidan AM.

Cancer. 2017 May 15;123(10):1703-1713. doi: 10.1002/cncr.30585. Epub 2017 Feb 13. Review.

48.

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

Stahl M, Zeidan AM.

Cancer. 2017 May 15;123(6):911-914. doi: 10.1002/cncr.30532. Epub 2017 Jan 17. No abstract available.

49.

Therapy-related myelodysplastic syndromes, or are they?

Abou Zahr A, Kavi AM, Mukherjee S, Zeidan AM.

Blood Rev. 2017 May;31(3):119-128. doi: 10.1016/j.blre.2016.11.002. Epub 2016 Nov 24. Review.

PMID:
27923516
50.

Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016.

Zeidan AM, Battiwalla M, Berlyne D, Winkler T.

Leuk Res. 2017 Feb;53:8-12. doi: 10.1016/j.leukres.2016.11.011. Epub 2016 Nov 24. Review.

PMID:
27923195

Supplemental Content

Loading ...
Support Center